Obesity drug Mounjaro to surpass Ozempic with $27 bn sales in 2029: Report
New York, Dec 18(IANS) Eli Lilly's Mounjaro is poised to surpass Novo Nordisk's Ozempic (semaglutide) and become the leading drug by sales in the obesity and diabetes market, according to a report on Monday.